Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Adenosine Receptor A3 (ADORA3) - Overview
Adenosine Receptor A3 (ADORA3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development
Acorn Biomedical Inc
BioIntervene Inc
Can-Fite BioPharma Ltd
Future Medicine Co Ltd
Palo BioFarma SL
Adenosine Receptor A3 (ADORA3) - Drug Profiles
ACN-1052 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Agonize ADORA3 for Chemotherapy Induced Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-1302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJ-1888 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJ-2698 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
modenoson - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-1650 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-677 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piclidenoson - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ADORA3 for Chronic Obstructive Pulmory Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ADORA3 for Kidney Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target A3AR for Sexual Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Adenosine Receptor A3 (ADORA3) - Dormant Products
Adenosine Receptor A3 (ADORA3) - Discontinued Products
Adenosine Receptor A3 (ADORA3) - Product Development Milestones
Featured News & Press Releases
Dec 09, 2019: Can-Fite completes 50% patient enrollment in its phase III Psoriasis Trial
Dec 05, 2019: Can-Fite to attend BioFIT 2019 Conference in Europe with focus on partnering meetings for modenoson in SH
Nov 19, 2019: Can-Fite granted patents for its sexual dysfunction drug
Nov 11, 2019: Can-Fite granted U.S. Patent for piclidenoson in the treatment of osteoarthritis, positioning this indication for animal health market
Nov 04, 2019: Can-Fite initiates compassiote use program for modenoson in the treatment of liver cancer, enrolls and treats patients
Oct 31, 2019: U.S. FDA agreed with Can-Fite’s proposed pivotal phase III trial design to support a new drug application submission and approval of modenoson in the treatment of Liver Cancer
Oct 17, 2019: Can-Fite and Gebro Pharma holding European Conference on development & commercialization of phase III drug candidate Piclidenoson in the treatment of Rheumatoid Arthritis
Oct 15, 2019: Can-Fite completes patient enrollment in phase II SH study of modenoson
Oct 10, 2019: Can Fite announces publication of modenoson SH mechanism of action in Intertiol Jourl of Molecular Medicine
Sep 23, 2019: Can-Fite presents new data on the treatment of advanced liver cancer with modenoson at the ILCA Conference
Sep 23, 2019: Can-Fite presents new data on the treatment of advanced liver cancer with modenoson at the ILCA Conference
Aug 06, 2019: Can-Fite to treat Advanced Liver Cancer patients with modenoson under compassiote use setting in Israel
Jun 04, 2019: Can-Fite Participating in One-on-One Partnering Meeting for Piclidenoson at the BIO Intertiol Convention on June 3-6, 2019
Jun 04, 2019: Can-Fite Participating in One-on-One Partnering Meetings at the BIO Intertiol Convention on June 3-6, 2019
Jun 03, 2019: Findings from Can-Fites phase II Liver Cancer Study were presented at ASCO Annual Meeting Late-Breaking Session
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Acorn Biomedical Inc, H2 2019
Pipeline by BioIntervene Inc, H2 2019
Pipeline by Can-Fite BioPharma Ltd, H2 2019
Pipeline by Future Medicine Co Ltd, H2 2019
Pipeline by Palo BioFarma SL, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019